The concentration of anti gout drugs in the market is gradually increasing

[market analysis of chinapharma.com] with the improvement of people's living standards, many chronic diseases closely related to diet have also attracted people's attention Gout is the first one According to the data monitoring of five drug terminals of Zhongkang CMH, the sales volume of targeted anti gout drugs in the domestic market in 2014 was 408 million yuan, reaching 507 million yuan in 2015, and the market is expected to expand to 631 million yuan in 2016 (Baidu pictures) with the changing lifestyle and diet structure of the modern people, the incidence rate of gout is increasing Now it has become the second metabolic disease after diabetes mellitus, and the incidence of the disease is showing an annual trend of light In modern people's diet, such as beer, seafood, animal viscera, bean products, strong tea and so on, they often induce gout attack But like diabetes, gout is a fully controllable disease Gout is a kind of chronic metabolic disease It is necessary to control the blood uric acid at the target level for a long time in order to effectively prevent chronic damage On the one hand, it is necessary to adjust the lifestyle (such as low purine diet, abstinence from alcohol, weight loss, etc.) to keep the blood uric acid normal On the other hand, it is necessary to use drugs for a long time in principle, otherwise, it is likely to lead to the rise of blood uric acid and recurrent gout According to the data monitoring of five drug terminals of Zhongkang CMH, the sales volume of targeted anti gout drugs in the domestic market in 2014 was 408 million yuan, reaching 507 million yuan in 2015, and the market is expected to expand to 631 million yuan in 2016 The drug market is highly concentrated, and a single variety of benzbromarone has accounted for 50% of the market In order to promote the excretion of uric acid, benzbromarone is currently a major category of anti gout drugs, accounting for nearly 50% of the market share of anti gout drugs However, this is a good performance of this category, which will be affected by the listing of several new drugs It is expected that the market share of benzbromarone will decline in 2016 As an anti gout special research drug approved for marketing in 2013, non bustat is a potential new star in the anti gout market, with rapid growth It is expected that its market share will increase to 20.2% in 2016 Allopurinol is a kind of drug which can inhibit the production of uric acid, accounting for about 20% of the anti gout market It can also be seen that patients with gout have a better understanding of the causes of gout, and can reduce the production of uric acid through other ways (such as diet control), so that they have a lower dependence on drugs that inhibit the production of uric acid Colchicine is often used as an analgesic for acute gout induced arthritis However, due to its large toxic and side effects, the market share will gradually decline under the attack of non Brest drugs with better safety According to the five terminal monitoring of CMH, at present, the anti gout drugs are mainly led by ligalixian (benbromarone tablets (Herman, Germany)), youlitong (non bustard tablets (Wanbang biochemistry, Jiangsu)) and ertongshu (benbromarone tablets (Yichang Yangtze River Pharmaceutical Industry)) The market performance is as follows: the product concentration of anti gout drug market is relatively high, and the market share of benbromarone tablets (German Herman (subpackaged)) is more than 30% However, with the gradual emergence of non Bustan market power and the gradual increase of sales, the market share of benbromarone tablets will decline in the future.